1[1]Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study(4S) [J]. Lancet, 1994,344 (8934): 1383-1389.
2[2]Osborne JA, Lento PH, Siegfried MR, et al. Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment[J].J Clin Invest, 1989,83(2):465-473.
3[3]LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. AHA Medical/Scientific Statement, Special Report [ J]. Circulation 1990, 90 ( 8 ):1721-1733.
4[4]Laufs U, La Fata V, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase[J]. J Biol Chem, 1997,272(50): 31725-31729.
5[5]Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase[ J]. J Biol Chem, 1998,273 ( 37 ): 24266-24271.
6[6]Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)CoA reductase inhibitors mediated by endothelial nitric oxide synthase[J]. Proc Natl Acad Sci USA 1998,95 (15):8880-8885.
7[7]Lefer AM,Campboll B,Shin YK, et al.Simvastatin preserves the ischemic-repefused myocardium in normocholesterolemic rat hearts[J]. Circulation, 1999,100(2): 178-184.
8[8]Prufer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats [J]. Arterioscler Thromb Vasc Biol, 1999,19 ( 12 ):2894-2900.
9[9]Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble Pselectin and ICAM-1 levels in hypercholesterolemic patients:role of nitric oxide[J] .J Invest Med,2000,48(3) :183-189.
10[10]Burke AP, Kolodigie FD, Frab A, et al. Healed plaque ruptures and coronary death:evidence that subclinical rupture has a role in plaque progression[J]. Circulation,2001,103(7) :936-940.
5Koichiro Y, Kazuyoshi K. MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis. J pathology, 2002, 198:388-396.
6Raymond F. Increased phosphorylated extraeellular signal regulated kinase immunoreactivity associated with proliferative and morphologic lung alterations after chrgsotile asbestos inhalation in mice, AM J Pathology, 2000, 156: 1307-1316.
7Andreas A, Dagmar S, Thomas R, et al, Transforming growth factor-β1 induced activation of the raf-MEK-MAPK signaling pathway in rat lung fibroblasts via a PKC-dependent mechanism . Biochem Biophys Res Commun, 1998,249:456-460.
8Aviram M, Hussein O, Rosenblat M,et al. Interactions of platelets,macrophages, and lipoproteins in hypercholesterolemia : an tiatherogenic effects of HMG-CoA reductase inhibitor therapy[ J]. J Cardiovasc Pharmacol, 1998,31 ( 1 ) :39-45.
9Relou IA, Hackeng CM, Akkerman JW, et al. Low-density lipoprotein and its effect on human blood platelets[ J]. Cell Mol Life Sci, 2003,60(5) :961-971.
10Laufs U, Gertz K, Dirnagl U, et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice [ J ]. Brain Res, 2002, 942(1/2) :23-30.
